Ironwood Pharmaceuticals
IRWD
199 hedge funds and large institutions have $1.95B invested in Ironwood Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 67 increasing their positions, 61 reducing their positions, and 29 closing their positions.
143% more call options, than puts
Call options by funds: $15.9M | Put options by funds: $6.56M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
26% more capital invested
Capital invested by funds: $1.55B → $1.95B (+$408M)
5% more funds holding
Funds holding: 190 → 199 (+9)
10% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 61
0.25% less ownership
Funds ownership: 107.46% → 107.21% (-0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$18M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$13.7M |
| 3 |
Renaissance Technologies
New York
|
+$11.9M |
| 4 |
Goldman Sachs
New York
|
+$11.5M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$30.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 3 |
BlackRock
New York
|
-$11.4M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$11.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.61M |
IRWD Hedge Fund Activity: Q4 2020 in Review
199 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2020, worth a combined $1.95B — up 26% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IRWD positions and 29 closed out — a net gain of 9 holders — while 67 added to existing stakes and 61 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $18M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $30.5M sold.
- 199 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2020, up from 190 in Q3 2020.
- Funds reported $1.95B of Ironwood Pharmaceuticals stock for Q4 2020, up 26% quarter-over-quarter.
- 38 funds opened new Ironwood Pharmaceuticals positions in Q4 2020 and 29 closed out, a net change of +9 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2020 was Westfield Capital Management, an estimated $18M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2020 was Janus Henderson Group, an estimated $30.5M sold.
Based on aggregated 13F filings for Q4 2020.